A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens

Advances in Therapy

Volumn 28, Issue 11, 2011, Pages 1000-1011

  Xie, Lin ^a   Wei, Wenhui ^b   Pan, Chunshen ^c   Du, Juan ^a   Baser, Onur ^a  

^a STATINMED RESEARCH   (United States)

^b SANOFI   (France)

^c ProUnlimited   (United States)

Author keywords

clinical outcomes; economic outcomes; insulin detemir; insulin glargine; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; MEGLITINIDE; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISPOSABLE EQUIPMENT; DISPOSABLE PENS; ECONOMIC ASPECT; FEMALE; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PROPENSITY SCORE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DISPOSABLE EQUIPMENT; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT PREFERENCE; RETROSPECTIVE STUDIES;

EID: 82355180949     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0074-5     Document Type: Article

References (32)

1. J.E. Shaw R.A. Sicree P.Z. Zimmet 2010 Global estimates of the prevalence of diabetes for 2010 and 2030 Diabetes Res Clin Pract 87 4 14 19896746 10.1016/j.diabres.2009.10.007 1:STN:280:DC%2BC3c%2Fot1Witg%3D%3D
2. R. Sturm 2008 Stemming the global obesity epidemic: what can we learn from data about social and economic trends? Public Health 122 739 746 18490037 10.1016/j.puhe.2008.01.004
3. J.O. Hill H.R. Wyatt G.W. Reed J.C. Peters 2003 Obesity and the environment: where do we go from here? Science 299 853 855 12574618 10.1126/science.1079857 1:CAS:528:DC%2BD3sXpt1Sgtw%3D%3D (Pubitemid 36182434)
4. Centers for Disease ControlPrevention. 2011 National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 US Department of Health and Human Services, Centers for Disease Control and Prevention Atlanta, GA. Available at: www.cdc.gov/diabetes/ pubs/pdf/ndfs-2011.pdf. Last accessed October 13, 2011.
5. American Diabetes Association. 2008 Economic costs of diabetes in the U.S. in 2007 Diabetes Care 31 596 615 10.2337/dc08-9017
6. T.K. Mattila A. de Boer 2010 Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus Drugs 70 2229 2245 21080740 10.2165/11585220-000000000-00000 1:CAS:528:DC%2BC3MXltl2rug%3D%3D
7. S. Kim 2007 Burden of hospitalizations primarily due to incontrolled diabetes: implications of inadequate primary health care in the United States Diabetes Care 30 1281 1282 17290038 10.2337/dc06-2070 (Pubitemid 46684664)
8. A. Morsanutto P. Berto S. Lopatriello, et al. 2006 Major complications have an impact on total annual medical cost of diabetes: results of a database analysis J Diabetes Complications 20 163 169 16632236 10.1016/j.jdiacomp.2005. 06.011
9. The Diabetes ControlComplications Trial Research Group. 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 977 986 10.1056/NEJM199309303291401 (Pubitemid 23307905)
10. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-853.
11. American Diabetes Association. 2011 Standards of medical care in diabetes-2011 Diabetes Care 34 Suppl.1 S11 S61 10.2337/dc11-S011
12. Rodbard HW, Jellinger PS, Davidson JA, et al. 2009 AACE/ACE Consensus Statement: Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Available at: http://alt.aace.com/pub/pdf/ GlycemicControlAlgorithm.pdf. Last accessed October 13, 2011.
13. Department of Health and Human Services, Centers for Disease Control and Prevention. 2010 Diabetes Data & Trends. Treating Diabetes (insulin and oral medication use). Available at: www.cdc.gov/diabetes/statistics/treating- national.htm. Last accessed October 13, 2011.
14. J. Rosenstock M. Davies P.D. Home J. Larsen C. Koenen G. Schernthaner 2008 A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulinnaive people with type 2 diabetes Diabetologia 51 408 416 18204830 10.1007/s00125-007-0911-x 1:CAS:528:DC%2BD1cXhtlyls7c%3D
15. S. Heller C. Koenen B. Bode 2009 Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallelgroup, treat-to-target noninferiority trial Clin Ther 31 2086 2097 19922879 10.1016/j.clinthera.2009.10.006 1:CAS:528:DC%2BD1MXhsFGlsrbI
16. P. Raskin T. Gylvin W. Weng L. Chaykin 2009 Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes Diabetes Metab Res Rev 25 542 548 19565569 10.1002/dmrr.989 1:CAS:528:DC%2BD1MXht1Gntr3P
17. J.B. Marks 2008 How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab 4 490 491 18594486 10.1038/ncpendmet0900 1:CAS:528:DC%2BD1cXhtVSitr3J
18. J. Gordon R.D. Pockett A.P. Tetlow P. McEwan P.D. Home 2010 A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study Int J Clin Pract 64 1609 1618 20946269 10.1111/j.1742-1241.2010.02520.x 1:CAS:528:DC%2BC3cXhsVantr3L
19. S.G. Swinnen M.P. Dain R. Aronson, et al. 2010 A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs Diabetes Care 33 1176 1178 20200301 10.2337/dc09-2294 1:CAS:528:DC%2BC3cXotFKiu7k%3D
20. L.R. Reynolds 2010 Comparing insulins detemir and glargine in type 2 diabetes: more similarities than differences. Commentary Postgrad Med 122 201 203 20107306 10.3810/pgm.2010.01.2116
21. C. Coscelli S. Lostia M. Lunetta I. Nosari G.A. Coronel 1995 Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old Diabetes Res Clin Pract 28 173 177 8529495 10.1016/0168-8227(95) 01092-R 1:STN:280:DyaK287gsFGruw%3D%3D
22. A. Kadiri A. Chraibi F. Marouan, et al. 1998 Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents Diabetes Res Clin Pract 41 15 23 9768368 10.1016/S0168-8227(98)00055-2 1:CAS:528:DyaK1cXkvFOrsLk%3D (Pubitemid 28394280)
23. M. Korytkowski D. Bell C. Jacobsen R. Suwannasari FlexPen Study Team 2003 A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus Clin Ther 25 2836 2848 14693308 10.1016/S0149-2918(03)80337-5 1:CAS:528:DC%2BD2cXhtVyntg%3D%3D (Pubitemid 37510593)
24. K. Keith D. Nicholson D. Rogers 2004 Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump Clin Pediatr (Phila) 43 69 74 10.1177/000992280404300109 (Pubitemid 38112268)
25. O. Baser J. Bouchard T. DeLuzio H. Henk M. Aagren 2010 Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe Adv Ther 27 94 104 20352392 10.1007/s12325-010-0009-6
26. P.R. Rosenbaum D.B. Rubin 1983 The central role of the propensity score in observational studies for causal effects Biometrika 70 41 55 10.1093/biomet/70.1.41
27. S.K. Garg 2010 The role of basal insulin and glucagonlike peptide-1 agonists in the therapeutic management of type 2 diabetes-a comprehensive review Diabetes Technol Ther 12 11 24 20082581 10.1089/dia.2009.0127 1:CAS:528:DC%2BC3cXntVWrtA%3D%3D
28. S. Pscherer E.S. Dietrich F.W. Dippel A.R. Neilson 2010 Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany Int J Clin Pharmacol Ther 48 129 137 20137765 1:CAS:528:DC%2BC3cXjtlGms74%3D
29. A.L. Guillermin Y. Samyshkin D. Wright T. Nguyen J. Villeneuve 2011 Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis J Med Econ 14 207 216 21361858 10.3111/13696998.2011.561390
30. S.G. Swinnen A.C. Simon F. Holleman J.B. Hoekstra J.H. Devries 2011 Insulin detemir versus insulin glargine for type 2 diabetes mellitus Cochrane Database Syst Rev 7 CD006383 21735405
31. Pearl J. Understanding propensity scores. In: Causality: Models, Reasoning, and Inference. 2nd Edition. New York, NY: Cambridge University Press; 2009:348-351.
32. O. Baser 2009 Too much ado about instrumental variable approach: Is the cure worse than the disease? Value Health 12 1201 1209 19497084 10.1111/j.1524-4733.2009.00567.x